Talking HER2-Targeted Therapy With Dr. Ajani
April 4th 2020We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies.
Read More
Dr. Marshall Calls for Continued Discourse on Physician Burnout in Oncology
April 2nd 2020In our exclusive interview, Dr. Marshall provides his perspective on physician burnout in oncology, discusses the long-term personal and professional consequences of burnout, and shares ways to reduce oncology burnout on an individual and organizational level.
Read More
Collaborative Efforts Lead to the Launch of the COVID-19 and Cancer Consortium Registry
March 30th 2020Today, we passed the mic to Petros Grivas, MD, PhD, who moderated a discussion on a multi-institutional registry that has been created to capture data from healthcare professionals on patients with cancer who have suspected or confirmed diagnoses of the novel coronavirus, COVID-19. Joining Dr. Grivas is Jeremy L. Warner, MD, MS, as well as Ali R. Khaki, MD.
Read More
FLASCO Faculty Flesh Out Case Studies in GI Cancers
March 25th 2020Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.
Read More
Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers
March 11th 2020In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.
Read More
Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer
February 27th 2020Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.
Read More
FDA Grants Priority Review to Liso-Cel in Large B-Cell Lymphoma
February 13th 2020The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.
Read More
FDA Approval Sought for Selinexor in DLBCL
December 24th 2019An application has been submitted to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy.
Read More
FDA Approves Enfortumab Vedotin for Urothelial Cancer
December 19th 2019The FDA has approved enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.
Read More
FDA Approval Sought for Liso-Cel in Large B-Cell Lymphoma
December 19th 2019Bristol-Myers Squibb has submitted a biologics license application to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.
Read More
Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases
December 18th 2019Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.
Read More